natgillin/translations-raw huggingface dataset:
A compound according to claim 2, wherein the condition is lupus erythematosis. Use of a compound according to claim 1 to manufacture a medicament for use in the treatment of conditions or disorders mediated by S1 P1 receptors, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan 1 dijabetes neovisan o inzulinu.
A compound of formula (I) according to any one of claims 1 to 5, wherein R2 represents (C1-C4)alkyl, which is mono-substituted with an aryl- or heteroaryl-group, which groups are independently unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-C4)alkyl and -CH2NH2; 
predstavlja (C1-C4)alkil koji je mono-supstituiran s aril-skupinom ili heteroaril-skupinom, koje skupine su neovisno nesupstituirane, mono- ili di-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine (C1-C4)alkil i -CH2NH2;
Compositions as claimed in any one of claims 1 to 7, in the form of tablets that dissolve slowly in the oral cavity or chewing gums that release the active ingredients slowly, mouthwashes, gels for dispersal in the oral cavity, or the like. 
Pripravci kako su navedeni u patentnim zahtjevima 1 do 7, naznačeni time da su u obliku tableta koje se polako otapaju u oralnoj šupljini ili guma za žvakanje koje polako oslobađaju aktivne tvari, vode za usta, gelova za disperziju u oralnoj šupljini i slično.
a cumulative total amount of phenylalanine per unit volume greater than 2.5 mM; 
(v) kumulativna ukupna količina fenilalanina po jedinici volumena veća od približno 2,5 mM;
A compound according to any one of claims 1-3, wherein R1 is and wherein subscript n' is selected from 1-5 and each R5 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy, aryloxy, alkoxycarbonyl, substituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted dialkylamino, halo, heteroaryloxy, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkyl, hydroxy, nitro, and thiol. 
su Ii su Uj i pri čemu je indeks n' odabran od 1-5 i svaki R> je neovisno odabran iz skupine koja sadrži vodik, supstituiran ili nesupstituiran alkil, supstituiran ili nesupstituiran acil, supstituiran ili nesupstituiran acilamino, supstituiran ili nesupstituiran alkilamino, supstituiran ili nesupstituiran alkiltio, supstituiran ili nesupstituiran alkoksi, ariloksi, alkoksikarbonil, supstituiran alkoksikarbonil, supstituiran ili nesupstituiran alkilarilamino, arilalkiloksi, supstituiran arilalkiloksi, amino, aril, supstituiran aril, arilalkil, sulfo, supstituiran sulfo, supstituiran sulfonil, supstituiran sulfinil, supstituiran sulfanil, azido, supstituiran ili nesupstituiran karbamoil, karboksil, cijano, supstituiran ili nesupstituiran cikloalkil, supstituiran ili nesupstituiran cikloheteroalkil, supstituiran ili nesupstituiran dialkilamino, halo, heteroariloksi, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran heteroalkil, hidroksi, nitro, i tiol.
A method for transmitting at least one broadcasting signal having Physical Layer Pipe, PLP, data for conveying a service stream, the method comprises: outer encoding the PLP data; 
Postupak odašiljanja barem jednog emitiranog signala s PLP podacima za prenošenje toka usluge, postupak obuhvaća: vanjsko kodiranje PLP podataka;
The veneer that is obtained from said beam-like block of wood by cutting (slicing)) is dried in order to reduce the humidity content below the fiber saturation point of the wood. 
Furnir koji se dobije od navedenog bloka od drva koji ima oblik grede pomoću rezanja (rezanja kriški) se suši da bi se tako smanjio sadržaj vlažnosti ispod točke zasićenja vlakana drva.
The anti-VEGF antibody of claim 36, wherein the administration of capecitabine is 1000 mg/m2 oral twice daily on Days 1-14 of each 3-week cycle and the administration of bevacizumab is 15mg/kg IV on day 1 of each 21-day cycle. 
Protutijelo anti-VEGF za uporabu prema zahtjevu 4, naznačeno time, da je primjena kapecitabina oralno dva puta dnevno po 1000 mg/m2 od prvog do četrnaestog dana svakog ciklusa od tri tjedna i primjena bevacizumaba je po 15 mg/kg IV prvoga dana svakog ciklusa od dvadesetjednog dana.
This fraction contains cell culture impurities and more basic isoforms of r-h IL-18BP. 
Ova frakcija sadrži nečistoće iz stanične kulture te vrlo bazične izooblike r-ML-18BP.
As shown in FIG. 12, the container 1100 is provided with a plurality of threads 1200 on the outer wall 1101 that allow the ring 1103 to be coupled to the container 1100 . 
Kako je prikazano na Slici 12, uz posudu 1100 ide više navoja 1200 na vanjskoj stijenci 1101 čime je omogućeno spajanje obruča 1103 na posudu 1100.
nonmagnetic members arranged radially outside of the tire mold and at intervals at a plurality of positions arranged in the circumferential direction of said ring members, and coupling both said ring members to each other; 
što su ne-magnetski članovi (13) raspoređeni u intervalima na više položaja koji se nalaze u obodnom smjeru prstenastih članova (11, 12), 1 oba prstenasta člana (11, 12) su međusobno spojena;
The method of claim 1, wherein each secondary dose is administered 1 to 8 weeks after the immediately preceding dose. The method of claim 1, wherein at least 8 secondary doses of the antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R) are administered to the subject, and wherein each secondary dose is administered 1 week after the immediately preceding dose. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 7-9, naznačen time što se svaka sekundarna doza primjenjuje 1 do 8 tjedana neposredno nakon prethodne doze, ili pri čemu se najmanje 8 sekundarnih doza protutijela ili njegovog ulomka koji veže antigen koji specifično veže interleukin-4 receptor (IL-4R) primjenjuju na subjekta, i pri čemu svaka sekundarna doza se primjenjuje 1 tjedan neposredno nakon prethodne doze.
deprotecting a compound of Formula XXVII to give a compound of Formula XXVIII 
R2-H Formula IX čime se dobiva spoj Formule XXVII:
Drug substance and vaccine products are frequently provided in vials which are closed with an elastomer closure part through which a hollow needle can be passed, puncturing the closure part, and via which the drug substance or vaccine product may be extracted for use, optionally after reconstitution by an aqueous medium introduced into the vial via the needle. 
Ljekovite tvari i proizvodi za cijepljenje se često dobavljaju u bočicama koje su zatvorene s elementom za zatvaranje, kojemu je dio načinjen od elastomera i kroz koji može proći šuplja igla bušeći element za zatvaranje, pri čemu se kroz šuplju iglu može izvući ljekovita tvar ili proizvod za cijepljenje radi njihovog korištenja, po potrebi nakon rekonstitucije s vodenim sredstvom koje se uvodi u bočicu kroz ovu iglu.
The high protein, fruit-flavoured beverage according to any one of the preceding embodiments, wherein the fruit flavouring agent also contains food acid. 
Visokoproteinski napitak s voćnom aromom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sredstvo za davanje voćne arome također sadrži prehrambenu kiselinu.
A compound of Formula I-E: wherein A, B, C, and D are independently selected from CR1 and N; wherein at least one of A, B, C, and D is CR1; wherein R1 is selected from H, alkyl, heteroalkyl, aryl, arylalkyl, halogen; and wherein when two adjacent of A, B, C, and D are CR1, the two R1's may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; 
[image] gdje su A, B, C i D nezavisno izabrani od CR1 i N; gdje je najmanje jedan od A, B, C i D jednak CR1; gdje je R1 izabran od H, alkil, heteroalkil, aril, arilalkil, halogen grupe; i gdje kada su dva susjedna od A, B, C i D jednaka CR1, dva R1 mogu se spojiti tako da formiraju jednu aril, cikloalkil ili heterocikloalkil grupu;
For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner. 
Kod bukalne primjene pripravak može biti u obliku tableta ili lozengeta, formuliranih na konvencionalan način.
The container 13 preferably contains an amount of fluid which is sufficient for multiple applications, particularly for a predetermined period of application such as one month, or for at least 50, preferably at least 100 doses or atomisations. 
Spremnik 13 sadrži ponajprije količinu fluida koja je dovoljna za više aplikacija, posebno za prethodno određen period aplikacija kao što je jedan mjesec, ili za najmanje 50, ponajprije najmanje 100 doza ili atomizacija.
For example, when moieties activate the intracellular response upon binding to the receptor, or enhance GTP binding to membranes. TABLE 1 
Na primjer, kada udio aktivira intracelularni odgovor zbog vezanja na receptor ili poboljša GTP vezanje na membrane.
with the exclusion of the following compounds: 
sa izuzetkom sljedećeg spoja:
The method of claim 1, wherein the compound is administered in the form of a cream. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
A solid system for the modified release in accordance with claim 4, wherein the microgranules comprise an active ingredient and an amphiphilic adjuvant. 
Čvrsti sustav za modificirano oslobađanje u skladu s patentnim zahtjevom 4, naznačen time što mikrogranule sadrže aktivni sastojak i amfifilni adjuvans.
This analysis was carried out in the frame of three independent experiments. 
Ova analiza je bila provedena u tri neovisna eksperimenta
The method as described in any of items 21 to 26 wherein said monitoring of said disease comprises determining regression, course or onset of said disease in a sample from a patient who has said disease or is suspected of falling ill with said disease. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
The method of claim 9, wherein said viral vector is replication-defective. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni virusni vektor replikacijski manjkav.
Garment, according to claim 1, characterized in that the content of polyethylene covering the synthetic fibres is in the range of 0,1% and 0,3% in weight. 
Odjevni predmet u skladu s patentnim zahtjevom 1, naznačen time, da je sadržaj polietilena koji pokriva sintetička vlakna u rasponu od 0,1 % do 0,3 % težine u odnosu na ukupnu težinu odjeće.
The method of claim 1, wherein the pain is chronic pain. 
Spoj za uporabu prema zahtjevu 34, gdje je bol kronična bol.
extracting said escitalopram with an organic solvent; 
ekstrakciju escitaloprama organskim otapalom;
The controlled release characteristics of the lozenges allow self-titration of the drug dosage by the patient. 
Osobine tableta koje su vezane za kontrolirano oslobađanje omogućuju da pacijent sam može odrediti dozu lijeka.
The pharmaceutical preparation according to claim 4 which is used as a vasodilator, hypotensive drug, aquaretic agent, or platelet aggregation inhibitor. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time, da se upotrebljava kao vazodilator, hipotenzivni lijek, akvauretičko sredstvo ili inhibitor agregacije pločastih stanica.
The device according to claim 17, comprising means allowing the introduction of air through the orifices, wherein said means are made up of or comprise sweeping elements such as fringe or bristles. 
Uređaj prema zahtjevu 13, naznačen time da su sredstva koja omogućavaju uvođenje zraka kroz otvore (40) oblikovana sa ili sadrže elemente za brisanje, kao što su rese ili čekinje (41).
A pharmaceutical formulation according to claim 1, wherein said phospholipid has a purity higher than 80%. 
Farmaceutska formulacija prema patentnim zahtjevima 1 ili 2, naznačeno time da fosfolipid jest fosfatidilkolin ili njegova smjesa s lecitinom.
wherein the compound is a compound of formula (I) 
Spoj s formulom (I) [image] naznačen time da
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Spoj prema zahtjevu 7, naznačen time, da je to: 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)- amid, ili njegova farmaceutski prihvatljiva sol.
The solution is subjected to microwave irradiation in a sealed reaction vessel with stirring at 60°C over 45 minutes. The reaction mixture is evaporated to dryness in vacuo. 
Otopinu se podvrgne mikrovalnom zračenju u začepljenoj reakcijskoj posudi uz miješanje 45 minuta pri 60"C. Reakcijsku smjesu se ispari do suhog u vakuumu.
vulcanizing the introduced rubber or plastic material, so that a first lower layer (20, 120) of the tread is formed which embeds, and presses against the pins, the single element (18) or the localized elements (130a, 130b, 130c, 130d), and forming a first intermediate component (21), and 
- vulkaniziranje uvedenog gumenog ili plastičnog materijala, tako da se formira prvi niži sloj (20, 120) gazišta koji se usađuje 1 pritišće na čavliće, na izdvojeni element (18) ili na lokalizirane elemente (130a, 130b, 130c, 130d), tvoreći time prvu međuslojnu komponentu (21), 1
The crude material is dissolved in minimum volume of acetone and water (5 mL) is added to it. 
Sirovi materijal otopi se u minimalnom volumenu acetona, te se tome doda voda (5 ml).
The compound as claimed in claim 2, wherein X is a substituted phenyl ring. The compound as claimed in claim 5, wherein said phenyl ring is substituted with A, and A is at least one member selected from the group of —H, —OH and —F. 
Spoj prema patentnom zahtjevu 4, naznačen time što X je supstituirani fenil prsten; poželjno navedeni fenil prsten je supstituiran sa A, i A je najmanje jedan član izabran iz grupe koju čine -H, -OH i -F, i Y je poželjno -COOH.
The humanized antibody of any of claims 7 to 11, for the use of those claims, wherein the amyloidogenic disease characterized by amyloid deposits of AB in the brain is Alzheimer's disease. 
Humanizirano antitijelo prema bilo kojem od patentnih zahtjeva 7 do 11, za upotrebu prema tim patentnim zahtjevima, naznačeno time da je amiloidogena bolest koju karakteriziraju amiloidne naslage AB u mozgu Alzheimerova bolest.
A product or composition according to any one of the preceding claims, further comprising at least one additional active compound. 
Sastav 1z bilo kojeg od prethodnih patentnih zahtjeva, nadalje obuhvaća najmanje jednu dodatnu aktivnu tvar.
The lipid particle of claim 6, wherein the particle further comprises a non-cationic lipid. The lipid particle of claim 7, wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol or a derivative thereof, or a mixture of a phospholipid and cholesterol or a derivative thereof. 
Čestica lipida u skladu s patentnim zahtjevom 5, naznačena time, da čestica nadalje sadrži ne-kationski lipid, poželjno odabran iz skupine koja se sastoji od fosfolipida, kolesterola ili kolesterol derivata, ili smjese fosfolipida i kolesterola ili kolesterol derivata, pri čemu fosfolipid poželjno sadrži dipalmitoilfosfatidilkolin (DPPC), distearoilfosfatidil-kolin (DSPO), ili njihovu smjesu.
A dispenser according to clause 17 comprising a third ring member being coaxially arranged about said longitudinal axis. 
HR P20180379 T1 Dispenzer sukladno zahtjevu 12 koji sadrži treći prstenasti dio (1502) koji je koaksijalno raspoređen oko navedene uzdužne osi (214).
Use according to Claim 2 or Claim 3, wherein, in the compound of formula la, the structural fragment is in the S - configuration at the C-atom to which R1a is attached. 
Uporaba prema zahtjevu 2 ili zahtjevu 3, naznačena time da, u spoju s formulom 1a, strukturni fragment HR P20171553 T1 R'"
The pharmaceutical composition for use as claimed in Claim 9, which is for anti-rheumatoid arthritis. 
Farmaceutski sastav za uporabu prema zahtjevu 9, naznačen time, da treba djelovati protiv reumatoidnog artritisa.
The reaction mixture was quenched in cold water. 
Reakcijska smjesa je ugašena u hladnoj vodi.
receiving modulated data pseudo-streams through respective transmission channels; demodulating said first and said at least one second data pseudo-streams through a first and at least one second demodulators, respectively; 
demodulacije navedenog prvog (9c) i navedenog najmanje jednog drugog (9d) pseudo-toka podataka preko prvog (10) i najmanje jednog drugog (11) demodulatora, redom;
The isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising: a heavy chain variable region comprising: 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) i makaki CD38 (SEQ ID NO:2) koje sadrži: a) = varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:9; b) varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10; 1 c) - kovalentno vezan dio lijeka.
Accordingly, the present invention relates to a pharmaceutical combination comprising as components 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I) optionally in form of one of its pure stereolsomers, in particular an enantiomer or a diastereomer, a racemate or in form of a mixture of its stereoisomers, in particular enantiomers and/or diastereomers in any mixing ratio, or any corresponding acid addition salt thereof, or any solvate thereof, and 
(a) barem jedan 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol formule (I), (D po mogućnosti u obliku jednog od njegovih čistih stereoizomera, posebno enantiomera ili dijastereoizomera, racemata ili u obliku smjese njegovih stereoizomera, posebno enantiomera i/ili dijastereoizomera u bilo kojem omjeru miješanja, ili bilo koje njegove odgovarajuće kiselinske adicijske soli, ili bilo kojeg njegovog solvata, i (b) paracetamol.
treating an ester of formula (1e) with methylamine; in a protic or aprotic solvent; at a temperature of about 0° C. to about 60° C.; to yield the corresponding compound (X). 
Q X tretiranja estera formule (1e) sa metilaminom; u protonskom ili aprotonskom otapalu; na temperaturi od približno 0 2C do oko 60 "C; da bi se dobio odgovarajući spoj (X).
Compound according to anyone of the preceding claims wherein Ar1 represents a Phenyl group optionally substituted by 1 up to 5 R group(s), wherein, each R, identical or different, is selected from the group consisting in Halogen atom, -Alkyl, -OAlkyl. 
Spoj prema bilo kojem od prethodnih patentnih zahtjeva, gdje Arl predstavlja Fenilnu skupinu izborno supstituirana s 1 do 5 R skupina, gdje, svakog R, istog ili različitog, se bira iz skupine koju čine Halogeni atom, -
The filtrate was evaporated and the resulting residue was purified using mass directed auto-preparative reverse phase HPLC to give the title compound (6.0 mg, 61%) as a white solid. 
Filtrat se otpari, a dobiveni ostatak pročisti maseno-ovisnim autopreparativnim HPLC-om s obratnom fazom kako bi se dobilo naslovni spoj (6,0 mg, 61 %) u obliku bijele krutine.
Use according to claim 1 or 2 wherein in formula (Ia) or (Ib) R1 is hydrogen, halo, Ar, alkyl or alkyloxy. 
Uporaba prema patentnom zahtjevu 1 ili 2, naznačena time da u formuli (la) ili (Ib) R! je vodik, halo, Ar, alkil ili alkiloksi.
The method according to claim 1, wherein in order to further strengthen an assembly margin of the membrane, a waterproof reinforcement element, comprising a waterproof heat-sealing tape, which is elastic and made of synthetic material, is applied directly to a lower edge of the membrane. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da se nepromočivi element za ojačavanje (651), radi dodatnog ojačavanja prepusta za montažu membrane, koja je poželjno elastična 1 izrađena od sintetičkih materijala, postavlja izravno na donji rub membrane.
FIGURE 3 is a side cross-section view of the container in Figure 1; 
je pogled sa strane na spremnik iz slike 1, s elementima spremnika u vertikalnom presjeku;
The present invention provides a compound which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, or a pharmaceutically acceptable salt thereof. 
PATENTNI ZAHTJEVI Spoj, naznačen time što je 3-(5-fluorpirimidin-4-il)-3-metil-6-(1A-pirazol-4-il)izoindolin-1-on, ili farmaceutski prihvatljiva sol ili njegov hidrat.
The composition according to claim 1, wherein the particle D50 of the cinacalcet HCl particles is less than or equal to about 50 um. 
Smjesa prema zahtjevu 8, gdje je Dso čestica sinakalcet HCI manji ili jednak 50 um.
The isolation system of claim 7, wherein said annular metal seal element (52) comprises an E-ring seal element. 
Izolacijski sustav prema zahtjevu 7, naznačen time, da spomenuti prstenasti metalni zaptivni element (52) obuhvaća E-prstenasti zaptivni element.
However, it has proven to be particularly advantageous if said equipment 65 for the application of an adhesive has a plurality of nozzles for the application of an adhesive (not shown here). 
Međutim, dokazano je da je naročito povoljno ako oprema za nanošenje ljepila 65 ima veći broj mlaznica za nanošenje ljepila (ovdje to nije prikazano).
Pirfenidone for use in treating a patient who would benefit from pirfenidone administration, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 1, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 1600 mg/dan u tijeku vremenskog perioda.
A B2 agonist as defined in claim 1 or 3, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 7 or 8. A B2 agonist for use according to claim 18 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.